Profusa jumps as it agrees to buy PanOmics diagnostics platform

Profusa

06/04/2026 11:10

** Shares of Digital health firm Profusa PFSA.O jump 93% to $1.46 premarket

**  Co says it signed a letter of intent to acquire BioInsights’ PanOmics molecular diagnostics platform in a roughly $30 mln all-stock deal

** PFSA says the deal gives Profusa exclusive rights to the technology plus access to clinical samples to validate new diagnostic tests

** PFSA says the first focus will be pancreatic cancer, a hard-to-treat cancer often needing complex surgery

** Co says it is expanding work with Mayo Clinic to monitor patients before and after pancreatic surgeries using the platform

** BioInsights to receive 3% royalty on net revenue and can nominate a Profusa board member - PFSA

** PFSA says it plans to raise additional funding to scale the diagnostics business

** As of last close, stock down ~90% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))